Abstract
The prognosis for patients with non-small cell lung cancer (NSCLC) remains poor in spite of better treatments. This relates mainly to the fact that the majority of patients present with advanced disease. There is a need to identify tools which can improve screening for lung cancer in the at risk patient population. The aim of this study was to compare the breath proteomic profile of NSCLC patients with healthy control subjects to explore the potential of new biomarkers of lung cancer. Comparative proteomic analysis of exhaled breath condensate (EBC) between 14 patients with NSCLC and 13 healthy control subjects were carried out using LTQ FT Ultra mass spectrometry and database searching to determine any unique proteins. In total, 29 unique proteins were identified using multiple protein identification algorithms. A comparison of lung cancer, smoker, and ex-smoker proteomes showed that 18 proteins were shared among the three groups. While one unique protein was found in smokers and lung cancer patients, four proteins were unique to ex-smokers. This data set provides a foundation for evaluation of these proteins from EBC as potential biomarkers for non-invasive lung cancer diagnosis.
Highlights
Lung cancer is a major cause of cancer-related death in industrialized countries worldwide [1]
Comparative proteomic analysis of exhaled breath condensate (EBC) between 14 patients with non-small cell lung cancer (NSCLC) and 13 healthy control subjects were carried out using LTQ FT Ultra mass spectrometry and database searching to determine any unique proteins
In an effort to further our understanding of lung cancer biology and to identify new candidate biomarkers to be used in the management of lung cancer, the aim of this study was to probe EBC with the LTQ FT Ultra Mass Spectrometry to conduct a proteomic comparison between patients with NSCLC and matched volunteers
Summary
Lung cancer is a major cause of cancer-related death in industrialized countries worldwide [1]. Despite advances in diagnosis and treatment strategies in the last decade, prognosis of NSCLC patients is poor with a 5-year overall survival of 16%, the lowest of any cancer [2,3]. Diagnosis of lung cancer is performed currently by sputum cytology, interval chest x-rays, computed tomography (CT) scans, and bronchoscopy, with cytopathologic examination of bronchoalveolar lavage, endobronchial brushings and biopsies obtained from the area of abnormality. Most of these tests are invasive and expensive, and there are often delays in establishing the diagnosis and initiating treatment. To improve lung cancer management and survival, there is a need to develop screening and early diagnostic strategies that are sensitive, specific, and non-invasive
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
